Asthma treatment: Antileukotriene drugs

Canadian Respiratory Journal

Volumn 5, Issue SUPPL. A, 1998, Pages

  O'Byrne, Paul M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antileukotrienes; Asthma; Cysteinyl leukotrienes; Leukotrienes

Indexed keywords

ANTIASTHMATIC AGENT; CYSTEINYL LEUKOTRIENE RECEPTOR 2; LEUKOTRIENE; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEMBRANE PROTEIN;

ASTHMA; BIOSYNTHESIS; BRONCHOSPASM; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; HUMAN; ORAL DRUG ADMINISTRATION; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHOCONSTRICTION; CONTROLLED CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MEMBRANE PROTEINS; PROGNOSIS; RECEPTORS, LEUKOTRIENE; TREATMENT OUTCOME;

EID: 0032109330     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Hargreave FE, Gibson PG, Ramsdale EH. Airway hyperresponsiveness, airway inflammation, and asthma. Immunol Allergy Clin North Am 1990;10:439-48.
2. Kirby JG, Hargreave FE, Gleich GJ, O'Byrne PM. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis 1987;136:379-83.